Trial reportJournal of cancer research and clinical oncology2023
A practical nomogram and risk stratification system for predicting survival outcomes in neuroblastoma patients: a SEER population-based study.
Trial report in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Machine learning prediction model for distant metastasis at diagnosis in pediatric neuroblastoma: development, interpretation, and temporal validation.Translational pediatrics · 2026Article
- Multiparametric MRI radiomics for noninvasive risk stratification of pediatric neuroblastoma: a pilot study.Scientific reports · 2026Article
- Development and internal validation of an XGBoost-based prognostic prediction model and risk stratification system for overall survival in pediatric neuroblastoma: a SEER-based study.Translational pediatrics · 2026Article
- Single-Cell RNA Sequencing Reveals Lactylation Modifications in Neuroblastoma and the Construction of a Prognostic Model.Molecules (Basel, Switzerland) · 2026Article
- A dynamic nomogram and risk stratification system for predicting cancer-specific survival in patients with locally advanced differentiated thyroid cancer: a population-based study.Gland surgery · 2025Article
- Genetically predicted interleukin 7 levels and neuroblastoma risk combined with analysis of radiation therapy timing effects.Discover oncology · 2025Article
- Surgical Treatment of Adrenal Neuroblastoma in Children - A Narrative Review.International braz j urol : official journal of the Brazilian Society of UrologyReview
- Stratification of Anatomical Imaging Features Between High-Risk and Non-High-Risk Groups in Neuroblastoma.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroblastoma (NB) is a childhood malignancy with marked heterogeneity, resulting in highly variable outcomes among patients. This study aims to establish a novel nomogram and risk stratification system to predict the overall survival (OS) for patients with NB.
methodsWe analyzed neuroblastoma patients from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2015. The nomogram was constructed using independent risk factors for OS, identified through univariate and multivariate Cox regression analyses. The accuracy of this nomogram was evaluated with the concordance index, receiver operating characteristic curve, calibration curve, and decision curve analysis. In addition, we developed a risk stratification system based on the total score of each patient in the nomogram.
resultsA total of 2185 patients were randomly assigned to the training group and the testing group. Six risk factors, including age, chemotherapy, brain metastases, primary site, tumor stage, and tumor size, were identified in the training group. Using these factors, a nomogram was constructed to predict 1-, 3-, and 5-year OS of NB patients. This model exhibited superior accuracy in the training and testing groups, exceeding traditional tumor stage prediction. Subgroup analysis suggested worse prognosis for retroperitoneal origin in the intermediate-risk group and adrenal gland origin in the high-risk group compared to other sites. Additionally, the prognosis for high-risk patients significantly improved after surgery. We also developed a web application to make the nomogram more user-friendly in clinical practices.
conclusionThis nomogram demonstrates excellent accuracy and reliability, offering more precise personalized prognostic predictions to clinical patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.